Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

Loo et al., Pharmaceutical Research, doi:10.1007/s11095-023-03520-1
Apr 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Review of nanoformulations for inhaled therapeutics for respiratory viral infections including COVID-19.
Inhaled formulations can deliver treatment directly to the respiratory tract, enabling higher concentrations while minimising systemic side effects, and providing a solution for instability and low solubility issues.
This study includes ivermectin and HCQ.
Loo et al., 25 Apr 2023, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections
Ching-Yee Loo, Wing-Hin Lee, Qi Tony Zhou
Pharmaceutical Research, doi:10.1007/s11095-023-03520-1
With the rapid outbreak of respiratory viral infections, various biological (e.g. vaccines, peptides, recombinant proteins, antibodies and genes) and antiviral agents (e.g. ribavirin, palivizumab and valaciclovir) have been successfully developed for the treatment of respiratory virus infections such as influenza, respiratory syncytial virus and SARS-CoV-2 infections. These therapeutics are conventionally delivered via oral, intramuscular or injection route and are associated with several adverse events due to systemic toxicity. The inherent in vivo instability of biological therapeutics may hinder them from being administered without proper formulations. Therefore, we have witnessed a boom in nanotechnology coupled with a needle-free administration approach such as the inhalation route for the delivery of complex therapeutics to treat respiratory infections. This review discussed the recent advances in the inhalation strategies of nanoformulations that target virus respiratory infections.
Author Contributions Ching-Yee Loo: Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published. Wing-Hin Lee: Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published. Qi Tony Zhou: Substantial contributions to the conception of the work; revising it critically for important intellectual content; final approval of the version to be published. Declarations Conflict of Interest The authors declare no conflict of interest to this review.
Akbal-Dagistan, Sevim, Sen, Basarir, Culha et al., Pulmonary delivery of favipiravir in rats reaches high local concentrations without causing oxidative lung injury or systemic side effects, Pharmaceutics
Albariqi, Chang, Tai, Ke, Chow et al., Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19, J Aerosol Med Pulm Drug Deliv
Albariqi, Wang, Chang, Quan, Wang et al., Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment, Int J Pharm
Ali, Alrashedi, Ahmed, Ibrahim, Pulmonary delivery of hydroxychloroquine nanostructured lipid carrier as a potential treatment of COVID-19, Polymers
Amorij, Saluja, Petersen, Hinrichs, Huckriede et al., Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice, Vaccine
Arnold, Buckner, Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection, Clin Transl Sci
Ascough, Vlachantoni, Kalyan, Haijema, Wallin-Weber et al., Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial, Am J Respir Crit Care Med
Assane, Makhtar, Abdoulaye, Amary, Djibril et al., Viral and Bacterial Etiologies of Acute Respiratory Infections Among Children Under 5 Years in Senegal, Microbiol Insights
Audouy, Van Der Schaaf, Hinrichs, Frijlink, Wilschut et al., Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization, Vaccine
Avery, Hoffmann, Whalen, The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review, Hosp Pharm
Aziz, Scherlieβ, Steckel, Development of high dose oseltamivir phosphate dry powder for inhalation therapy in viral pneumonia, Pharmaceutics
Baden, Sahly, Essink, Kotloff, Frey et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N Engl J Med
Baldassi, Ambike, Feuerherd, Cheng, Peeler et al., Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes, J Control Release
Bernstein, Malkin, Abughali, Falloon, Yi et al., Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children, Pediatr Infect Dis J
Bhide, Tomar, Dong, De Vries-Idema, Frijlink et al., Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus, Drug Deliv
Biagi, Dondi, Scarpini, Rocca, Vandini et al., Current state and challenges in developing respiratory syncytial virus vaccines, Vaccines
Buchholz, Cunningham, Muresan, Gnanashanmugam, Sato et al., International Maternal Pediatric Adolescent ACTPST. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children, J Infect Dis
Cai, Wang, Li, Gu, Sun et al., Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice, Acta Biochim Biophys Sin
Chauhan, Madou, Kalra, Chopra, Ghosh et al., Nanotechnology for COVID-19: Therapeutics and Vaccine Research, ACS Nano
Chemaly, Torres, Munsell, Shah, Rathod et al., An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection, J Infect Dis
Chen, Rosenberg, Cai, Lee, Shi et al., Nanotraps for the containment and clearance of SARS-CoV-2, Matter
Chinello, Petrosillo, Pittalis, Biava, Ippolito et al., QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient, PLOS Negl Trop Dis
Chorin, Dai, Shulman, Wadhwani, Bar-Cohen et al., The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin, Nat Med
Corritori, Savchuk, Pauza, Risk/benefit profiles of currently approved oral antivirals for treatment of COVID-19: similarities and differences, COVID
Cunningham, Piedra, Martinon-Torres, Szymanski, Brackeva et al., Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial, Lancet Respir Med
De Barros Aods, Pinto, Reis, Ricci-Junior, Alencar et al., Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect, J Nanostruct Chem
De Reus, Hagedoorn, Sturkenboom, Grasmeijer, Bolhuis et al., Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers, PLoS ONE
De Wit, Feldmann, Cronin, Jordan, Okumura et al., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc Natl Acad Sci
Degoey, Grampovnik, Flosi, Marsh, Wang et al., Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir, J Med Chem
Detalle, Stohr, Palomo, Piedra, Gilbert et al., Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection, Antimicrob Agents Chemother
Devincenzo, Cehelsky, Alvarez, Elbashir, Harborth et al., Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV), Antiviral Res
Dhakal, Renu, Ghimire, Lakshmanappa, Hogshead et al., Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs, Front Immunol
Dong, Wang, Gonzalez, Ma, Song et al., Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo-and heterologous strains, Proc Natl Acad Sci
Dong, Wang, Zhu, Ma, Kim et al., Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice, ACS Appl Mater Interfaces
Ebrahimi, Shamloo, Alishiri, Mofrad, Akherati, Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion, Int J Pharm
Esparza, Chen, Martin, Bielefeldt-Ohmann, Bowen et al., Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19, MAbs
Fassihi, Nabar, Fassihi, Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19, Br J Pharmacol
Fatkenheuer, Gillor, Platten, Kochanek, Salzberger, Aerosolized ribavirin for patients with cancer and respiratory syncytial virus infection, J Infect Dis
Fent, Avermectin, Encyclopedia of Toxicology
Finney, Glanville, Farne, Aniscenko, Fenwick et al., Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon, J Allergy Clin Immunol
Foolad, Aitken, Shigle, Prayag, Ghantoji et al., Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients, Clin Infect Dis
Frede, Neuhaus, Knuschke, Wadwa, Kollenda et al., Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation, Nanomedicine
Frediansyah, Nainu, Dhama, Mudatsir, Harapan, Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical epidemiology and global health
Ftouh, Kalboussi, Abid, Sfar, Mignet et al., Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses, PPAR Res
Gai, Ma, Li, Zhu, Qiao et al., A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential, MedComm
Garg, Latimer, Gerdts, Potter, Van Drunen Littel-Van Den Hurk, Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces longterm protective immunity against respiratory syncytial virus, Hum Vaccin Immunother
Garg, Theaker, Martinez, Van Drunen Littel-Van Den Hurk, A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus, Virology
Gomez, Mufson, Dubovsky, Knightly, Zeng et al., Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children, Pediatr Infect Dis J
Goodarzi, Morgani, Abrahamsson, Cristofoletti, Groot et al., Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin, J Pharm Sci
Gottlieb, Zamora, Hodges, Musk, Sommerwerk et al., ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients, J Heart Lung Transplant
Green, Sande, Scarselli, Capone, Vitelli et al., Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults, J Infect
Green, Scarselli, Sande, Thompson, De Lara et al., Chimpanzee adenovirusand MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults, Sci Trans Med
Green, Scarselli, Voysey, Capone, Vitelli et al., Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults, BMJ Open
Groneberg, Witt, Wagner, Chung, Fischer, Fundamentals of pulmonary drug delivery, Respir Med
Hajam, Senevirathne, Hewawaduge, Kim, Lee, Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens, Vet Res
Halevas, Mavroidi, Kokotidou, Moschona, Sagnou et al., Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery, J Drug Deliv Sci Technol
Haller, Miller, Mitiku, Coelingh, Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector, J Virol
Hanafy, El-Kemary, Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment, Int J Biol Macromol
Huang, Bernstein, Slobod, Portner, Takimoto et al., Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults, Hum Vaccin Immunother
Huo, Mikolajek, Bas, Clark, Sharma et al., A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19, Nat Commun
Ivanov, Oomens, Papin, Staats, Reuter et al., Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection, Vaccine
Jackson, Farzan, Chen, Choe, Mechanisms of SARS-CoV-2 entry into cells, Nat Rev Mol Cell Biol
Jamali, Mottaghitalab, Abdoli, Dinarvand, Esmailie et al., Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA, Drug Deliv Transl Res
Jara, Warnken, Sahakijpijarn, Moon, Maier et al., Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters, Int J Pharm
Jiao, Fu, Yan, Hua, Ma et al., A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus, Antiviral Res
Jin, Ren, Li, Gao, Zhang et al., Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019, EClinicalMedicine
Jin, Zhao, Lan, Zhou, Mai et al., Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury, Front Pharmacol
Jones, Sealy, Rudraraju, Traina-Dorge, Finneyfrock et al., Sendai virusbased RSV vaccine protects African green monkeys from RSV infection, Vaccine
Jones, Sealy, Surman, Portner, Russell et al., Sendai virusbased RSV vaccine protects against RSV challenge in an in vivo maternal antibody model, Vaccine
Kandeel, Al-Nazawi, Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease, Life Sci
Kapale, Chaudhari, Niclosamide & challenges in chemical modifications: A broad review on enhancement of solubility, J Indian Chem Soc
Karron, Luongo, Mateo, Wanionek, Collins et al., Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children, J Infect Dis
Karron, Luongo, Thumar, Loehr, Englund et al., A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children, Sci Trans Med
Khaitov, Nikonova, Shilovskiy, Kozhikhova, Kofiadi et al., Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation, Allergy
Killikelly, Kanekiyo, Graham, Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus, Sci Rep
Klimke, Hefner, Will, Voss, Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection, Med Hypotheses
Knudson, Hartwig, Meyerholz, Varga, RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets, PLoS Pathog
Knuschke, Sokolova, Rotan, Wadwa, Tenbusch et al., Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection, J Immunol
Kocherlakota, Nagaraju, Arjun, Srinath, Kothapalli et al., Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19, Prostaglandins Leukot Essent Fatty Acids
Letko, Marzi, Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, Nat Microbiol
Li, Lin, Guo, Xia, Zhao et al., Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus, Int J Nanomedicine
Li, Song, Zhao, Tan, Zhao et al., Antiviral and Anti-Inflammatory Treatment with Multifunctional Alveolar Macrophage-Like Nanoparticles in a Surrogate Mouse Model of COVID-19, Advanced Science
Li, Wang, Dinh, Zhu, Popowski et al., Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19, Nat Nanotechnol
Li, Wu, Guo, Tang, Huang et al., Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial, Lancet Respir Med
Li, Zhan, Yang, Tu, Hu et al., Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody, Cell
Li, Zhang, Wu, Ren, Chu et al., Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19, Asian J Pharm Sci
Liao, Yuan, Cao, Tang, Qiu et al., Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus, Advanced Therapeutics
Lim, Cheong, Kim, Hwang, Lee et al., RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 prepandemic vaccine platform. Nanomed, Nanotechnol Biol Med
Lin, Li, Guo, Xiao, Wang et al., Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with zanamivir through p38 and JNK signaling pathways, RSC Adv
Lindell, Morris, White, Kallal, Lundy et al., A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease, PLoS ONE
Liu, Liang, Liu, Amaro-Carambot, Surman et al., Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates, PLoS ONE
Lo, Albariño, Perry, Chang, Tchesnokov et al., Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases, Proc Natl Acad Sci
Lokugamage, Vanover, Beyersdorf, Hatit, Rotolo et al., Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs, Nat Biomed Eng
Loo, Lee, Nanotechnology-based therapeutics for targeting inflammatory lung diseases, Nanomedicine (Lond)
Luczo, Bousse, Johnson, Jones, Pearce et al., Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets, Npj Vaccines
Mazur, Terstappen, Baral, Bardají, Beutels et al., Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape, Lancet Infect Dis
Mccoll, Croyle, Zamboni, Honer, Heise et al., COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics, Drug Metab Dispos
Mcfarland, Karron, Muresan, Cunningham, Libous et al., Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children, J Infect Dis
Mcfarland, Karron, Muresan, Cunningham, Perlowski et al., Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children, J Infect Dis
Mcfarland, Karron, Muresan, Cunningham, Valentine et al., Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children, J Infect Dis
Mora, Detalle, Gallup, Van Geelen, Stohr et al., Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs, MAbs
Nambulli, Xiang, Tilston-Lunel, Rennick, Sang et al., Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses, Sci Adv
Ndeupen, Qin, Jacobsen, Bouteau, Estanbouli et al., The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory, iScience
Neemann, Freifeld, Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation, Curr Infect Dis Rep
Nelson, Dileepan, Rasley, Jenkins, Fischer et al., Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge, J Virol
Nelson, Tang, Stillman, Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells, Vaccine
O'konek, Makidon, Landers, Cao, Malinczak et al., Intranasal nanoemulsionbased inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats, Hum Vaccin Immunother
Patil, Murugappan, Veer, Meijerhof, De Haan et al., Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine, J Control Release
Pekoz, Dagistan, Fael, Culha, Erturk et al., Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis, Drug Deliv
Polack, Thomas, Kitchin, Absalon, Gurtman et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med
Russell, Hurwitz, Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses, Expert Rev Vaccines
Sahakijpijarn, Moon, Koleng, Christensen, Iii, Development of remdesivir as a dry powder for inhalation by Thin Film Freezing, Pharmaceutics
Sahakijpijarn, Moon, Warnken, Maier, Devore et al., In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters, Int J Pharm X
Sahastrabudhe, Kenjale, Pokharkar, Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler: <i>In-Vitro</i> Characterization and <i>In-Vivo</i> Toxicological Studies, Curr Drug Deliv
Sawaengsak, Mori, Yamanishi, Mitrevej, Sinchaipanid, Chitosan nanoparticle encapsulated hemagglutininsplit influenza virus mucosal vaccine, AAPS PharmSciTech
Schoof, Faust, Saunders, Sangwan, Rezelj et al., An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike, Science
Shah, Chemaly, Management of RSV infections in adult recipients of hematopoietic stem cell transplantation, Blood
Shah, Ghantoji, Shah, Taoum, Jiang et al., Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections, J Antimicrob Chemother
Sheahan, Sims, Graham, Menachery, Gralinski et al., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med
Siegel, Hui, Doerffler, Clarke, Chun et al., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo
Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell et al., Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing, J Pediatr
Suberi, Grun, Mao, Israelow, Reschke et al., Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination, bioRxiv
Sun, Wang, Jia, Xia, Li et al., Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection, Viruses
Tai, Chow, Chang, Tang, Gonda et al., Nebulised isotonic hydroxychloroquine aerosols for potential treatment of COVID-19, Pharmaceutics
Tai, Wu, Wu, Tsai, Wang et al., A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study, Clin Transl Sci
Tang, Zhang, Lu, Jiang, Xi et al., Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation, Drug Delivery
Tao, Gill, M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection, Vaccine
Tao, Ziemer, Gill, Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus, Nanomedicine (Lond)
Tomar, Biel, De Haan, Rottier, Petrovsky et al., Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge, Eur J Pharm Biopharm
Trang, Whalen, Hilts-Horeczko, Doernberg, Liu, Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A singlecenter retrospective cohort study and review of the literature, Transpl Infect Dis
Tu, Wang, An, Qu, Li et al., Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants, Acta Pharm Sin B
Tulbah, Lee, Physicochemical characteristics and in vitro toxicity/Anti-SARS-CoV-2 activity of Favipiravir solid lipid nanoparticles (SLNs), Pharmaceuticals
Van Braeckel-Budimir, Haijema, Leenhouts, Bacteriumlike particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications, Front Immunol
Van Hoecke, Verbeke, Vlieger, Dewitte, Roose et al., mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice, Mol Therapy Nucleic Acids
Vartak, Patil, Patki, Kunda, Patel, Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro, Nanomedicine (Lond)
Várnai, Malanga, Sohajda, Béni, Molecular interactions in remdesivir-cyclodextrin systems, J Pharm Biomed Anal
Wang, Xiang, Lin, Cai, Ruan et al., Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm, Matter
Wang, Zhu, Luo, Wang, Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity, Nanomedicine
Wang, Zhu, Wang, Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro, Int J Nanomedicine
Warren, Jordan, Lo, Ray, Mackman et al., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature
Wu, Huang, Zhang, Wu, Zhang et al., Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial, Lancet Infect Dis
Zamora, Budev, Gottlieb, Humar, Devincenzo et al., RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus, Am J Respir Crit Care Med
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop